Italia markets closed

Alnylam Pharmaceuticals, Inc. (0HD2.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
214,03+3,21 (+1,52%)
Alla chiusura: 03:59PM BST
Schermo intero
Chiusura precedente210,82
Aperto208,16
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno208,16 - 214,03
Intervallo di 52 settimane208,16 - 214,03
Volume0
Media VolumeN/D
Capitalizzazione245,871M
Beta (5 anni mensile)0,57
Rapporto PE (ttm)N/D
EPS (ttm)-7,49
Prossima data utili26 ott 2022 - 31 ott 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

    Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announce